TELA Bio
General Information | |
Business: |
We are a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. We offer a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Our products are an innovative solution that integrate multiple layers of minimally-processed biologic material with interwoven polymers in a unique embroidered pattern, which we refer to as a reinforced tissue matrices. These products have been implanted by surgeons in more than 6,500 patients with no reported explantations due to failure of the product. |
Industry: | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Employees: | 86 |
Founded: | 2012 |
Contact Information | |
Address | 1 Great Valley Parkway, Suite 24, Malvern, PA 19355, US |
Phone Number | (484) 320-2930 |
Web Address | http://www.telabio.com |
View Prospectus: | TELA Bio |
Financial Information | |
Market Cap | $143.1mil |
Revenues | $11.2 mil (last 12 months) |
Net Income | $-27.1 mil (last 12 months) |
IPO Profile | |
Symbol | TELA |
Exchange | NASDAQ |
Shares (millions): | 4.0 |
Price range | $13.00 - $13.00 |
Est. $ Volume | $52.0 mil |
Manager / Joint Managers | Jefferies/ Piper Jaffray |
CO-Managers | Canaccord Genuity/ JMP Securities |
Expected To Trade: | 11/8/2019 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |